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Adolescent and young adult (AYA) reproductive healthcare needs are not diminished during 
pandemics. Indeed, needs for family planning services may be heightened due to a variety of 
environmental changes in response to the pandemic, including amount of parental 
supervision, daily structure, and usual ways of accessing contraception and condoms. 
Healthcare professionals (HCPs) caring for AYA patients need to acknowledge that 
contraception is an essential need and rapidly adopt new approaches to providing this crucial 
care.
In response to the COVID-19 pandemic HCPs are exploring novel ways to assure delivery of 
essential healthcare services and minimize exposure risks to personnel and patients, 
including virtual care. Fortunately, both phone and video platforms are well-suited to 
providing contraceptive care. While an in-person encounter may be ideal, many reproductive 
healthcare services can be performed virtually including contraception counseling, provision 
and maintenance of regular and emergency contraception, and sexual risk-reduction 
counseling. We propose the following approach for provision of contraception to adolescents 
during COVID-19, leveraging virtual care and minimizing the need for in-person visits 
(Figure 1). This approach can be used by a variety of HCPs from triage nurses to advanced 
care practitioners and across telehealth and in-person settings.
Safe provision of contraception relies largely on history and rarely requires a physical exam, 
pelvic or breast exams, sexually transmitted infection or cervical cancer screenings.1 Much 
of the information needed to provide contraceptives can be obtained from the patient history, 
including patient-reported or previously recorded blood pressure. The US Medical 
Eligibility Criteria for Contraceptive Use (US MEC) provides guidance on contraindications 
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to contraceptives based on the patient history and is available in many forms, including a 
smartphone app.1
A challenge in conducting telehealth with adolescents is patient privacy: adolescents may 
not have a private space and HCPs may not be able to reliably assess whether an 
adolescent’s verbal communication is actually private. It is important to explore who is in 
the room and if the patient can speak freely. We recommend using clinical judgement to 
guide whether you can safely ask about sensitive content and how much you need to obtain. 
It is not necessary to obtain a complete sexual history to prescribe contraceptives. Consider 
the use of yes/no questions for sensitive topics, such as interest in contraception, sexual 
history, and pregnancy screening.
Fortunately, a healthy young person with no active or previous medical conditions who takes 
no medications or supplements can safely use any reversible contraceptive method. Using 
contraception is very safe and is safer than pregnancy. In addition to uncovering medical 
contraindications from patient history, HCPs can ask a series of questions to be reasonably 
certain a person is not pregnant. If there are no signs or symptoms of pregnancy and the 
patient meets additional criteria as identified in the US MEC (see Figure 1), contraception 
other than intrauterine contraception can be started immediately.1 Even in situations where a 
HCP is not reasonably certain a person isn’t pregnant, the benefits of starting contraception 
that day (except intrauterine devices) generally outweigh the risks, as none of the 
contraceptive methods are known to be teratogenic or abortifacient.1 HCPs can encourage 
patients to take a home pregnancy test, which are highly reliable, in 2–4 weeks in these 
situations.
Contraception counseling can be performed virtually using shared decision making to 
incorporate patients’ preferences and priorities, which may include efficacy. Clinicians may 
consider incorporating high quality resources, including videos and images, such as those 
available at bedsider.org, prior to, during (screen-sharing), or after their virtual patient 
encounter.2 Pills, transdermal patch, and vaginal rings can be refilled or initiated on the day 
of the telehealth encounter and a 12-month supply should be provided.3 After initiation, use 
of a back-up method for 7 days is recommended. Progestin-only contraceptive pills 
(norethindrone and drosperinone) are an option for those with a contraindication to estrogen.
1
Depot medroxyprogesterone acetate (DMPA) is a progestin-only method available as a 
150mg intramuscular (IM) or 104mg subcutaneous (SC) injection. Traditionally, DMPA is 
administered every 3 months in a clinical setting. However, in pandemic times, HCPs can 
consider extending the dosing interval to 15 weeks and exploring creative approaches to IM 
delivery (e.g. curbside).1 Alternately, the SC form may be prescribed along with alcohol 
swabs for self-administration at home. Medication teaching can be provided verbally, by 
video and/or via a patient information sheet, such as this one made by Reproductive Health 
Access Project https://www.reproductiveaccess.org/resource/depo-subq-user-guide/.4
For the patient who is interested in a long-acting reversible contraceptive method (LARC, 
i.e. an intrauterine device (IUD) or implant), a shorter acting contraceptive should be offered 
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to provide contraception while awaiting in-person placement. People currently using a 
LARC nearing the end of their FDA-approved length of use can be reassured that these 
devices have contraceptive benefit far beyond the approved window.5
Counseling patients about the use of emergency contraception (EC) pills (i.e. levonorgestrel 
1.5mg and ulipristal acetate 30mg) and offering an advanced prescription may be 
particularly beneficial now to reduce patient cost and access barriers. Ulipristal acetate is 
more effective than levonorgestrel, particularly in those who have a BMI >30 or who had sex 
more than 72 hours ago. Patients who take ulipristal acetate for EC should wait 5 days to 
start a hormonal contraceptive and use condoms until their next menses. It is also important 
to encourage consistent condom use for STI prevention, back-up for birth control and dual 
protection. For any contraceptive method prescribed, clinicians should review options for 
obtaining the product. This may include purchasing or filling a prescription at a pharmacy 
and online/phone ordering with home delivery. After a method is chosen, HCPs should 
inform patient to contact them if there are additional and unforeseen cost or insurance 
coverage barriers during the pandemic.
In addition to these approaches, 11 states and the District of Columbia allow for pharmacist-
prescribed contraception. Further, some private companies provide telehealth options for 
home-delivery of contraceptives.6,7 However, we believe it is possible and imperative for 
HCPs to prioritize contraception access for young people throughout this pandemic and 
beyond as essential healthcare.
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Figure 1: Algorithm for Providing Contraception for Young People During a Pandemic
Abbreviations: AYA=Adolescents and Young Adults, HCP=Health Care Professional, US 
MEC= US Medical Eligibility Criteria for Contraceptive Use, BP=Blood Pressure, DMPA: 
Depot Medroxyprogesterone Acetate, LARC=Long-Acting Reversible Contraception, 
EC=Emergency Contraception
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